Company intelligence / Profile preview

Desitin Arzneimittel

Hamburg, Hamburg, Germanydesitinpharma.com ↗

Ownership: Private
Employees: ~290
Development stage: Other

Overview

Desitin Arzneimittel is a fully integrated, independent German pharmaceutical company focused on CNS diseases, particularly epilepsy and Parkinson's disease, with a broad range of in-house and in-licensed commercialized products in Europe. It specializes in small molecule drugs and has in the past out-licensed late-stage assets (e.g., sulthiame for sleep apnea). Clinical pipeline includes mature and established best-in-class CNS therapeutics.

Therapeutic areas: PulmonologyRare DiseasesNeurologyPsychiatry
Modalities: Small moleculeBiologic
Industry: Biotech

Drug pipeline

4 assets

Orfiril Long

Approved

3 more assets in the full pipeline.

Request access →

Partnerships

AFT Pharmaceuticals (Pascomer licensing)Apnimed/Shionogi (Sulthiame out-licensing for sleep apnea)

Beyond the preview

Go deeper on Desitin Arzneimittel.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Desitin Arzneimittel.

Explore the full profile